BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 12064870)

  • 1. Generation of EBV-specific CTLs suitable for adoptive immunotherapy of EBV-associated lymphoproliferative disease following allogeneic transplantation.
    Hoffmann T; Russell C; Vindelov L
    APMIS; 2002 Feb; 110(2):148-57. PubMed ID: 12064870
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes for the prevention and treatment of EBV-associated post-transplant lymphomas.
    Liu Z; Savoldo B; Huls H; Lopez T; Gee A; Wilson J; Brenner MK; Heslop HE; Rooney CM
    Recent Results Cancer Res; 2002; 159():123-33. PubMed ID: 11785836
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An Epstein-Barr virus deletion mutant associated with fatal lymphoproliferative disease unresponsive to therapy with virus-specific CTLs.
    Gottschalk S; Ng CY; Perez M; Smith CA; Sample C; Brenner MK; Heslop HE; Rooney CM
    Blood; 2001 Feb; 97(4):835-43. PubMed ID: 11159505
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Establishment and operation of a Good Manufacturing Practice-compliant allogeneic Epstein-Barr virus (EBV)-specific cytotoxic cell bank for the treatment of EBV-associated lymphoproliferative disease.
    Vickers MA; Wilkie GM; Robinson N; Rivera N; Haque T; Crawford DH; Barry J; Fraser N; Turner DM; Robertson V; Dyer P; Flanagan P; Newlands HR; Campbell J; Turner ML
    Br J Haematol; 2014 Nov; 167(3):402-10. PubMed ID: 25066775
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characteristics of human EBV-specific cytotoxic T lymphocytes utilized for adoptive immunotherapy of EBV-induced lymphoproliferations in xenografted SCID mice.
    Lacerda JF; O'Reilly RJ
    Ann Oncol; 1997; 8 Suppl 2():137-40. PubMed ID: 9209657
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment options for post-transplant lymphoproliferative disorder and other Epstein-Barr virus-associated malignancies.
    Davis JE; Moss DJ
    Tissue Antigens; 2004 Apr; 63(4):285-92. PubMed ID: 15009802
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adoptive immunotherapy with unselected or EBV-specific T cells for biopsy-proven EBV+ lymphomas after allogeneic hematopoietic cell transplantation.
    Doubrovina E; Oflaz-Sozmen B; Prockop SE; Kernan NA; Abramson S; Teruya-Feldstein J; Hedvat C; Chou JF; Heller G; Barker JN; Boulad F; Castro-Malaspina H; George D; Jakubowski A; Koehne G; Papadopoulos EB; Scaradavou A; Small TN; Khalaf R; Young JW; O'Reilly RJ
    Blood; 2012 Mar; 119(11):2644-56. PubMed ID: 22138512
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adoptive cellular immunotherapy for EBV lymphoproliferative disease.
    Heslop HE; Rooney CM
    Immunol Rev; 1997 Jun; 157():217-22. PubMed ID: 9255632
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immune-cell treatment of Epstein--Barr-virus-associated lymphoproliferative disorders.
    Swinnen LJ
    Best Pract Res Clin Haematol; 2006; 19(4):839-47. PubMed ID: 16997187
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunotherapy for Epstein-Barr virus-associated cancers.
    Rooney CM; Roskrow MA; Smith CA; Brenner MK; Heslop HE
    J Natl Cancer Inst Monogr; 1998; (23):89-93. PubMed ID: 9709309
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Activation and adoptive transfer of Epstein-Barr virus-specific cytotoxic T cells in solid organ transplant patients with posttransplant lymphoproliferative disease.
    Khanna R; Bell S; Sherritt M; Galbraith A; Burrows SR; Rafter L; Clarke B; Slaughter R; Falk MC; Douglass J; Williams T; Elliott SL; Moss DJ
    Proc Natl Acad Sci U S A; 1999 Aug; 96(18):10391-6. PubMed ID: 10468618
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Allogeneic cytotoxic T-cell therapy for EBV-positive posttransplantation lymphoproliferative disease: results of a phase 2 multicenter clinical trial.
    Haque T; Wilkie GM; Jones MM; Higgins CD; Urquhart G; Wingate P; Burns D; McAulay K; Turner M; Bellamy C; Amlot PL; Kelly D; MacGilchrist A; Gandhi MK; Swerdlow AJ; Crawford DH
    Blood; 2007 Aug; 110(4):1123-31. PubMed ID: 17468341
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epstein-Barr virus (EBV) load in bone marrow transplant recipients at risk to develop posttransplant lymphoproliferative disease: prophylactic infusion of EBV-specific cytotoxic T cells.
    Gustafsson A; Levitsky V; Zou JZ; Frisan T; Dalianis T; Ljungman P; Ringden O; Winiarski J; Ernberg I; Masucci MG
    Blood; 2000 Feb; 95(3):807-14. PubMed ID: 10648390
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epstein-Barr virus-specific cytotoxic T-lymphocytes for adoptive immunotherapy of post-transplant lymphoproliferative disease.
    Burns DM; Crawford DH
    Blood Rev; 2004 Sep; 18(3):193-209. PubMed ID: 15183903
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adoptive immunotherapy for Epstein-Barr virus-associated lymphoproliferative disorders complicating marrow allografts.
    O'Reilly RJ; Small TN; Papadopoulos E; Lucas K; Lacerda J; Koulova L
    Springer Semin Immunopathol; 1998; 20(3-4):455-91. PubMed ID: 9870257
    [No Abstract]   [Full Text] [Related]  

  • 16. Human Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes home preferentially to and induce selective regressions of autologous EBV-induced B cell lymphoproliferations in xenografted C.B-17 scid/scid mice.
    Lacerda JF; Ladanyi M; Louie DC; Fernandez JM; Papadopoulos EB; O'Reilly RJ
    J Exp Med; 1996 Mar; 183(3):1215-28. PubMed ID: 8642263
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of posttransplant lymphoproliferative disease in the central nervous system of a lung transplant recipient using allogeneic leukocytes.
    Emanuel DJ; Lucas KG; Mallory GB; Edwards-Brown MK; Pollok KE; Conrad PD; Robertson KA; Smith FO
    Transplantation; 1997 Jun; 63(11):1691-4. PubMed ID: 9197369
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epstein-Barr virus-associated lymphoproliferative disease after allogeneic haematopoietic stem cell transplantation: molecular monitoring and early treatment of high-risk patients.
    Meijer E; Cornelissen JJ
    Curr Opin Hematol; 2008 Nov; 15(6):576-85. PubMed ID: 18832928
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients.
    Heslop HE; Slobod KS; Pule MA; Hale GA; Rousseau A; Smith CA; Bollard CM; Liu H; Wu MF; Rochester RJ; Amrolia PJ; Hurwitz JL; Brenner MK; Rooney CM
    Blood; 2010 Feb; 115(5):925-35. PubMed ID: 19880495
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epstein-Barr virus-specific T-cell cytotoxicity is mediated through the perforin pathway in patients with lymphoproliferative disorders after allogeneic bone marrow transplantation.
    Yoshimi A; Tsuge I; Namizaki H; Hoshino Y; Kimura H; Takahashi Y; Watanabe N; Kuzushima K; Kojima S
    Br J Haematol; 2002 Mar; 116(3):710-5. PubMed ID: 11849237
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.